Propiverine Hydrochloride

Phase 2Small molecule

Propiverine Hydrochloride is one of 88 small molecule programs targeting Stress urinary incontinence. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stress Urinary IncontinenceActive, not recruiting

Interstitial CystitisActive, not recruiting

Overactive BladderActive, not recruiting

Stress Urinary IncontinencePreclinical

Active, not recruiting

Interstitial CystitisPreclinical

Active, not recruiting

Overactive BladderPhase 2

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Overactive Bladder

#DrugCompanyPhaseTrials

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

3 2

Botox

AbbVie

Phase 3

3 3

GSK1358820

GSK

Phase 3

1 4

Tolterodine PR

Pfizer

Phase 3

5 5

Oxybutynin Chloride

Mylan Pharmaceuticals Inc

Phase 3

3 6

Vesicare

Astellas

Phase 3

2 7

YM178

Astellas

Phase 3

6 8

SPM 907

Pfizer

Phase 3

5 9

Standard Medication Therapy

QQing Yuan

Phase 3

1 10

Onabotulinumtoxina 100 UNT

SStanford University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Overactive Bladder3 trials

Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder

Completed·AAPOGEPHA Arzneimittel GmbH·Phase 2·NCT00795925·30 enrolled

Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder

Completed·SSamsung Medical Center·Phase 4·NCT00903045·264 enrolled

Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder

Completed·LLee's Pharmaceutical Limited·Phase 3·NCT01512004·324 enrolled

Interstitial Cystitis1 trial

Effect of Interferential Electrical Stimulation on Pain Perception and Disability Level on Interstitial Cystitis

Completed·—·N/A·NCT03844581·40 enrolled

Stress urinary incontinence1 trial

Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride

Completed·TTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan·N/A·NCT01942681·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Propiverine Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Propiverine Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Propiverine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lee's Pharmaceutical Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLee's Pharmaceutical Limited

Propiverine Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Overactive Bladder3 trials

Interstitial Cystitis1 trial

Stress urinary incontinence1 trial

References

Drug Info

Quick Facts

Related News